Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward B Garon

Showing results (1-10 of 204) with videos related to

Pageof 21
Sort By:
Clinical Advances in Hematology & Oncology : H&O|February 2, 2024
Highlights in non-small cell lung cancer from the IASLC 2023 World Conference on Lung Cancer: commentaryEdward B Garon
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2020
Osimertinib plus Ramucirumab: The Best of Both Worlds?Edward B Garon
The Lancet. Oncology|February 10, 2016
The race for combined checkpoint inhibition in NSCLCEdward B Garon
Seminars in Oncology|October 20, 2015
Current Perspectives in Immunotherapy for Non-Small Cell Lung CancerEdward B Garon
The New England Journal of Medicine|June 22, 2017
Cancer Immunotherapy Trials Not Immune from Imprecise Selection of PatientsEdward B Garon
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Selecting patients for immune checkpoint inhibition in lung cancerEdward B Garon
Lung Cancer (Amsterdam, Netherlands)|July 17, 2012
Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancerEdward B Garon
Translational Cancer Research|January 16, 2023
Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustmentsArjan Gower, Edward B Garon
Med (New York, N.Y.)|May 19, 2022
Targeting more precisely: Improving sensitivity to EGFR inhibitors in NSCLCArjan Gower, Edward B Garon
Translational Cancer Research|March 26, 2019
Are lung adenocarcinoma mutations shaping the immune microenvironment?Philippe Rochigneux, Edward B Garon
Pageof 21

Showing results (1-10 of 204) with videos related to

Sort By:
Pageof 21
Clinical Advances in Hematology & Oncology : H&O|February 2, 2024
Highlights in non-small cell lung cancer from the IASLC 2023 World Conference on Lung Cancer: commentaryEdward B Garon
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2020
Osimertinib plus Ramucirumab: The Best of Both Worlds?Edward B Garon
The Lancet. Oncology|February 10, 2016
The race for combined checkpoint inhibition in NSCLCEdward B Garon
Seminars in Oncology|October 20, 2015
Current Perspectives in Immunotherapy for Non-Small Cell Lung CancerEdward B Garon
The New England Journal of Medicine|June 22, 2017
Cancer Immunotherapy Trials Not Immune from Imprecise Selection of PatientsEdward B Garon
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
Selecting patients for immune checkpoint inhibition in lung cancerEdward B Garon
Lung Cancer (Amsterdam, Netherlands)|July 17, 2012
Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancerEdward B Garon
Translational Cancer Research|January 16, 2023
Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustmentsArjan Gower, Edward B Garon
Med (New York, N.Y.)|May 19, 2022
Targeting more precisely: Improving sensitivity to EGFR inhibitors in NSCLCArjan Gower, Edward B Garon
Translational Cancer Research|March 26, 2019
Are lung adenocarcinoma mutations shaping the immune microenvironment?Philippe Rochigneux, Edward B Garon
Pageof 21